Table 4.
Univariate and multivariable analyses of factors associated with PFS.
| Factor | Univariable | Multivariable | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Male | 0.88 (0.60–1.29) | 0.513 | ||
| Age ≥65 years | 1.54 (1.08–2.20) | 0.018 | 1.37 (0.95–1.97) | 0.091 |
| NSCLC histology | ||||
| Adenocarcinoma | 1 | |||
| Squamous | 0.88 (0.61–1.27) | 0.498 | ||
| Other | 1.13 (0.52–2.45) | 0.764 | ||
| ECOG ≥2 | 2.51 (1.34–4.71) | 0.004 | 1.97 (1.03–3.76) | 0.04 |
| No change in weight before treatment | 1.15 (0.92–1.43) | 0.216 | ||
| Smoking history | ||||
| No | 1 | |||
| Yes | 0.92 (0.64–1.32) | 0.64 | ||
| Unknown | 1.36 (0.49–3.77) | 0.555 | ||
| EGFR status | ||||
| Wild type | 1 | 1 | ||
| Mutant | 1.89 (1.03–3.47) | 0.039 | 1.76 (0.93–3.31) | 0.082 |
| Unknown | 0.86 (0.57–1.31) | 0.491 | 0.86 (0.56–1.30) | 0.469 |
| ALK status | ||||
| Wild type | 1 | |||
| Fusion | 0.00 (0.00–1.25E162) | 0.959 | ||
| Unknown | 0.73 (0.48–1.12) | 0.154 | ||
| Lines of immunotherapy | ||||
| First line | 1 | 1 | ||
| Second line | 1.99 (1.32–3.00) | 0.001 | 1.75 (1.15–2.65) | 0.008 |
| Third line and above | 1.64 (1.06–2.53) | 0.026 | 1.43 (0.91–2.25) | 0.119 |
| Type of drug, Anti-PD-L1 | 0.56 (0.36–0.87) | 0.01 | 0.73 (0.45–1.19) | 0.204 |
| Therapeutic modalities | ||||
| Single drug | 1 | 1 | ||
| Combined with chemotherapy | 0.73 (0.51–1.04) | 0.083 | 0.82 (0.48–1.39) | 0.459 |
| Combined with CTLA-4 | 0.79 (0.34–1.84) | 0.588 | 1.82 (0.69–4.82) | 0.23 |
| Others | 0.32 (0.04–2.27) | 0.252 | 0.34 (0.04–2.65) | 0.305 |
| irAE | 0.54 (0.37–0.77) | 0.001 | 0.62 (0.43–0.91) | 0.015 |
PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; irAE, immunotherapy-related adverse events; ECOG, Eastern Cooperative Oncology Group; EGFR, epithelial growth factor receptor; ALK, anaplastic lymphoma kinase; Bold values indicate P-values <0.05, considered statistically significant.